Mr. Henry Dubina reports

TELESCOPE INNOVATIONS SECURES THIRD SELF-DRIVING LAB DEPLOYMENT WITH MAJOR GLOBAL PHARMACEUTICAL COMPANY

Telescope Innovations Corp. has signed an agreement with a major global pharmaceutical company to deliver a self-driving lab platform at the company's European operations. The deployment, Telescope's third SDL placement in its 2026 fiscal year, is expected to be installed within the coming months.

A milestone building on two prior successes

The agreement marks a significant milestone for Telescope, which has secured three SDL deployments in a single fiscal year with pharmaceutical companies that rank among the world's largest by revenue. Earlier this fiscal year, the company installed SDL platforms at the Korean Pharmaceutical and Biopharma Manufacturers Association (see news release dated Dec. 9, 2025) and at Pfizer (see news release dated Feb. 23, 2026). The addition of a third top-tier global pharmaceutical company, this time in Europe, demonstrates broadening international demand for Telescope's autonomous lab technology and validates the company's ability to serve the most demanding research and development environments in the industry.

About self-driving labs

SDLs, or self-driving labs, are physical experimental platforms that integrate robotic automation, advanced process analytics and artificial intelligence. The SDL autonomously executes chemistry experiments while associated analytical instruments evaluate the outcomes in real time. This set-up also enables machine learning algorithms to determine the optimal subsequent experiment. The full, iterative cycle dramatically accelerates the optimization of complex chemistry while reducing the need for manual intervention.

This latest SDL is specifically designed to address crystallization, one of the most critical yet traditionally time-intensive stages of pharmaceutical development. The project reflects confidence in Telescope's ability to automate high-value, scientifically demanding workflows.

Technical execution has built commercial momentum

"A key to Telescope's SDL approach is flexibility," noted Dr. Jason Hein, Telescope chief technology officer. "Our reconfigurable hardware and software let us rapidly build and deliver new workflows, like this crystallization-specific platform. We're proud of our adaptability, especially as pharma companies are increasingly seeking to combine new and legacy equipment into a wide variety of automation workflows."

Henry Dubina, Telescope chief executive officer, commented: "We're encouraged by the continued momentum that we are developing with top-tier pharmaceutical partners. Each new SDL deployment expands our global footprint and reflects increasing confidence in our ability to deliver this physical AI technology. We're excited to be leading the global transition with our biopharmaceutical partners for autonomous labs to significantly improve their essential R&D infrastructure."

About Telescope Innovations Corp.

Telescope is a developer of reaction sampling technology, intelligent automation and advanced chemical manufacturing technologies. The company builds and deploys enabling technologies, including reaction sampling systems for real-time analysis, flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency and data quality. The company's self-driving labs are fully autonomous, physical AI platforms that plan, execute and analyze experiments far more efficiently than traditional manual approaches. Biopharmaceutical, high-value specialty chemical and advanced material companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market.

We seek Safe Harbor.